Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | PLAU | P00749 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29569681 | 1.00 | HDAC1 (0.45) | HDAC1EGFRKDM4EGLAMAPT | |
| Hydrochloric Acid SCHEMBL16277747 | 0.98 | HDAC1 (0.44) | HDAC1EGFRKDM4EGLAMAPT | |
| Hydrochloric Acid SCHEMBL15158292 | 0.98 | HDAC1 (0.44) | HDAC1EGFRKDM4EGLAMAPT | |
| Nitrous Acid SCHEMBL20529700 | 0.89 | HDAC1 (0.46) | HDAC1EGFRKDM4EGLAMAPT | |
| SCHEMBL30698896 | 0.85 | HDAC1 (0.42) | HDAC1EGFRKDM4EGLAMAPT | |
| SCHEMBL956895 | 0.82 | PRKCI (0.50) | HDAC1EGFRKDM4EGLAMAPT | |
| SCHEMBL12190764 | 0.78 | APP (0.37) | KDM4EMAPTPOLBMAPK1HTT | |
| SCHEMBL18576423 | 0.77 | KDM4E (0.45) | HDAC1KDM4EGLAMAPTPOLB | |
| SCHEMBL31708248 | 0.77 | LMNA (0.49) | HDAC1KDM4EGLAMAPTPOLB | |
| SCHEMBL8200994 | 0.77 | HDAC1 (0.42) | HDAC1KDM4EGLAMAPTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 352 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | INTERLINE THERAPEUTICS INC (US) | 2026-05-21 | — | — | US | disclosed |
| EP-4105216-B1 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GENFLEET THERAPEUTICS SHANGHAI INC (CN) | 2026-05-20 | — | — | EP | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | DIFFERENTIATED THERAPEUTICS INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-12540127-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| EP-3976604-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2026-01-21 | — | — | EP | disclosed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| US-20090170859-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-07-02 | — | — | US | disclosed |
| WO-2009079011-A1 | BENZIMIDAZOLES AND ANALOGS AS RHO KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-06-25 | — | — | WO | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009017664-A1 | CYCLIC INHIBITORS OF 11β-HYDROXYSTERIOD DEHYDROGENASE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | EFREMOV IVAN | 2008-11-13 | — | — | US | disclosed |
| WO-2008012623-A1 | BENZIMIDAZOLYL COMPOUNDS AS POTENTIATORS OF MGLUR2 SUBTYPE OF GLUTAMATE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2008-01-31 | — | — | WO | disclosed |
| WO-2007135527-A2 | BENZIMIDAZOLYL COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007062342-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | HDAC1 160/4885EGFR 455/4885KDM4E 1888/4885 |
| US-20080280933-A1 | BENZIMIDAZOLYL COMPOUNDS | PAICS, TMBIM6, ABCG2 | HDAC1 608/4885EGFR 1414/4885KDM4E 2254/4885 |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | HDAC1 19/4885EGFR 475/4885KDM4E 1344/4885 |
| US-20260137706-A1 | METHODS OF TREATING INFLAMMATORY DISEASES | NR3C1, CCR1, CXCR2 | HDAC1 149/4885EGFR 2231/4885KDM4E 3867/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | HDAC1 1768/4885EGFR 337/4885KDM4E 4744/4885 |
| US-20260042762-A1 | MERTK DEGRADERS AND USES THEREOF | MERTK, CRKL, OSTC | HDAC1 399/4885EGFR 294/4885KDM4E 1946/4885 |
| US-12540127-B2 | CRBN ligands and uses thereof | CRBN, NR2C2, NR2E3 | HDAC1 349/4885EGFR 185/4885KDM4E 3572/4885 |
| US-20090170859-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | HDAC1 1089/4885EGFR 2414/4885KDM4E 2636/4885 |
| US-20260070917-A1 | CYCLIN DEPENDENT KINASE DEGRADERS AND METHODS OF USE THEREOF | CDK2, CCNK, CCNC | HDAC1 388/4885EGFR 197/4885KDM4E 320/4885 |
| US-20260085075-A1 | PROTEIN DEGRADERS AND USES THEREOF | NR2C2, SRR, NCOR2 | HDAC1 428/4885EGFR 519/4885KDM4E 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.